{"id":"W2295354328","doi":"10.1016/s1470-2045(15)00614-2","title":"Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":470,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Ignyta; National Institutes of Health; University of Washington; Astex Pharmaceuticals; Eli Lilly and Company; Novartis Institutes for BioMedical Research; Ariad Pharmaceuticals; Genentech; Pfizer; Novartis Pharmaceuticals Corporation; Chugai Pharmaceutical; Servier; Universität Heidelberg","keywords":"Ceritinib; Crizotinib; Medicine; ALK inhibitor; Internal medicine; Anaplastic lymphoma kinase; Lung cancer; Oncology; Tyrosine-kinase inhibitor; Clinical trial; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003031051,0.001226548,0.002963015,0.0003539024,0.0003035282,0.001207069,0.0007081483,0.001309749,0.002192087],"category_scores_gemma":[0.002645606,0.0003669455,0.003056121,0.0004350575,0.0007380106,0.001715413,0.0003055554,0.003054186,0.0004606333],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001114125,"about_ca_system_score_gemma":0.0006733339,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006678578,"about_ca_topic_score_gemma":0.002456298,"domain_scores_codex":[0.9991541,0.0003807857,0.00006431372,0.0001568422,0.0001186147,0.0001252742],"domain_scores_gemma":[0.9983461,0.0005648005,0.0005948362,0.0001056642,0.0001225751,0.0002660388],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7273095,0.003201728,0.01596294,0.003908011,0.01020954,0.0001850101,0.0002222714,0.004605023,0.01020618,0.000412207,0.01044752,0.21333],"study_design_scores_gemma":[0.6735234,0.1895769,0.1005252,0.000449734,0.01114412,0.001278118,0.000185766,0.002928129,0.0048647,0.001416998,0.01392567,0.0001813646],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9529435,0.03831324,0.0005601856,0.001309927,0.0004222483,0.0004272729,0.002598141,0.0001689789,0.003256598],"genre_scores_gemma":[0.9885972,0.005591814,0.0004890693,0.0008191311,0.0002917338,0.0001756308,0.002888914,0.00003508889,0.001111609],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003031051,"threshold_uncertainty_score":0.01602989,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04046967010096525,"score_gpt":0.3862219429664884,"score_spread":0.3457522728655231,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}